Furthermore, it has been reported that after treating NSCLC cells carrying ALK rearrangement with alectinib in vivo and in vitro, the YAP1 can be activated, which mediates alectinib resistance by upregulating anti-apoptotic factors Mcl-1 and Bcl-xL [152]. The gene discussed is BCL2L1; the disease is non-small cell lung carcinoma.